Clinical trials in 2013 indicate that omalizumab is effective in patients with recalcitrant, antihistamine-resistant chronic idiopathic urticaria, including those cases of autoimmune cause.
Ten percent of patients report skin eruptions (such as macules and papules), urticaria, dermatitis, fever, and arthralgia; 0.03% of all patients develop agranulocytosis.
